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Despite the urgent need for sustained development of novel antibacterial compounds to
combat the drastic rise in antibiotic resistant and emerging bacterial infections, only a few
clinically relevant antibacterial drugs have been recently developed. One of the bottlenecks
impeding the development of novel antibacterial compounds is the identification of
new enzymatic targets. The nutritionally essential amino acid anabolic pathways, for
example lysine biosynthesis, provide an opportunity to explore the development of
antibacterial compounds, since human genomes do not possess the genes necessary
to synthesize these amino acids de novo. The diaminopimelate (DAP)/lysine (lys) anabolic
pathways are attractive targets for antibacterial development since the penultimate lys
precursor meso-DAP (m-DAP) is a cross-linking amino acid in the peptidoglycan (PG)
cell wall of most Gram-negative bacteria and lys plays a similar role in the PG of most
Gram-positive bacteria, in addition to its role as one of the 20 proteogenic amino acids.
The L,L-diaminopimelate aminotransferase (DapL) pathway was recently identified as a
novel variant of the DAP/lys anabolic pathways. The DapL pathway has been identified in
the pathogenic bacteria belonging to the genus; Chlamydia, Leptospira, and Treponema.
The dapL gene has been identified in the genomes of 381 or approximately 13% of
the 2771 bacteria that have been sequenced, annotated and reposited in the NCBI
database, as of May 23, 2014. The narrow distribution of the DapL pathway in the bacterial
domain provides an opportunity for the development and or discovery of narrow spectrum
antibacterial compounds.
Keywords: amino acid, antibacterial, antibiotic, lysine, pyridoxal-5′-phosphate, diaminopimelate,
L,L-diaminopimelate aminotransferase, peptidoglycan
INTRODUCTION
The rise in the number of multidrug-resistant bacteria has led to
a significant increase in the morbidity and mortality of humans
infected with pathogenic bacteria. As such, the development
and/or discovery of novel antibacterial compounds critical for the
improvement of human health are necessary to combat current
and emerging bacterial infections and/or diseases. Antibacterial
agents generally fall into two classes of compounds; bactericidal
and bacteriostatic. Bactericidal means that the compound is able
to kill the bacteria while bacteriostatic means that the agent is able
to prevent growth of the bacteria (Pankey and Sabath, 2004).
Of the 20 common proteogenic amino acids, nine are con-
sidered nutritionally essential due to the fact that these nine
amino acids cannot be made by animals, particularly humans. As
such, these amino acids are deemed indispensable for growth and
development due to their overarching role in protein synthesis,
in addition to their roles in other pathways, and must be acquired
through dietarymeans. The amino acids that are deemed essential
are leucine, isoleucine, valine, threonine, methionine, trypto-
phan, phenylalanine, histidine, and lysine. Of the nine, lysine is
of interest since the pathway is also important for the synthesis of
the peptidoglycan (PG) cell wall in bacteria.
In nature, the essential amino acid lysine (lys) is syn-
thesized by certain organisms utilizing one of two pathways.
The α-aminoadipic acid (AAA) pathway is predominantly
employed by fungi and is present in a few species belonging
to the domain archaea (Nishida et al., 1999; Velasco et al.,
2002). Photosynthetic organisms and most bacteria employ the
diaminopimelate (DAP) pathway. To date, four variants of the
DAP/lys anabolic pathways has been elucidated and characterized.
The acyl pathways, which utilize succinylated (succinyl-CoA) or
acetylated (acetyl-CoA) intermediates, is present in most bac-
terial species; the meso-diaminopimelate (m-DAP) dehydroge-
nase (Ddh) pathway, which was initially discovered in Bacillus
sphaericus, Corynebacterium glutamicum, and Brevibacterium sp.
(Misono et al., 1976, 1979a,b, 1986; White, 1983), and the
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recently discovered L,L-diaminopimelate (L,L-DAP) aminotrans-
ferase (DapL) variant pathway (Hudson et al., 2006, 2008; McCoy
et al., 2006) (Figure 1). The synthesis of lysine de novo from the
DAP pathways can be divided into three main steps. The first
step characterized by the synthesis of tetrahydrodipicolinate acid
(THDP) from aspartate (asp) is a general feature of all four vari-
ants. This conversion is carried out in a series of reactions by
the enzymes; LysC (EC: 2.7.2.4), asd (EC: 1.2.1.11), DapA (EC:
4.2.1.52), and DapB (EC: 1.2.1.26) (Figure 1A). The second step,
which constitutes the conversion of THDPA to the penultimate
intermediate m-DAP, defines the uniqueness of the DAP vari-
ant pathways. In the acyl pathways, four enzymes needed for
the conversion of THDPA to m-DAP. These reactions are carried
out by the enzymes DapD (EC: 2.3.1.117), DapC (EC: 2.6.1.17),
DapE (EC: 3.5.1.18), and DapF (EC: 3.5.1.18) (Figure 1B). In
the diaminopimelate dehydrogenase (Ddh) (EC:1.4.1.16) path-
way,m-DAP is synthetized from THDP in a single reaction which
is capable of circumventing the DapD, DapC, DapE, and DapF
enzymatic steps that are present in the acyl pathways (Figure 1B).
In the L,L-diaminopimelate aminotransferase (DapL) pathway,
L,L-DAP is synthesize from THDP in a single transamination
reaction bypassing the DapD, DapC and DapE steps that are
present in acyl DAP pathways (Figure 1B). The conversion of
m-DAP to lysine via a decarboxylation reaction facilitated by
m-DAP decarboxylase (LysA EC: 4.1.1.20) defines the ultimate
step in the anabolism of lysine and it is a common feature of
the DAP/lys anabolic variants (Figure 1). The reaction definition
of each enzyme involved in the DAP/lys biosynthesis pathway is
presented in Table 1.
In addition to making lys for protein synthesis, the DAP/lys
pathways is also vital for the synthesis of the PG cell wall in most
bacteria. The bacterial cell wall has an important role in buffering
the internal and external forces. The cell wall is predominantly
composed of a cross-linked polymeric layer of β-1,4-linked disac-
charide of N-acetylglucosamine (GlcNAc) and N-acetylmumaric
acid (MurNAc) that is connected to a peptide stem. The pep-
tide stem is connected to MurNAc with the general sequence of
L-alanine-D-glutamate-X-D-alanine where the third amino acid
denoted by X is either m-DAP or lys (Figure 2A). m-DAP is the
cross linking amino acid in the cell wall of most Gram-negative
bacteria and lys serve a similar role in Gram-positive bacteria
(Hutton et al., 2007) (Figure 2B). The addition of m-DAP or lys
to PG is facilitated by the enzyme UDP-N-acetylmuramoylalanyl-
D-glutamate-2,6-diaminopimelate ligase (MurE) (EC 6.3.2.13)
(Figure 1). Given that the third amino acid is involved in cross-
linking, the lack of or incorrect incorporation of either m-DAP
or lys would lead to improper construction of the cell wall
and the inability of the bacterium to withstand the internal
osmotic pressure would ultimately lead to cell death via cell
lysis.
Inhibition of enzymes involved in the DAP/lys bacterial path-
ways would have a detrimental effect from two perspectives.
Firstly, since DAP or lys is involved in PG cross-linking, cell death
via lysis would occur as a result of osmotic pressure from the
lack of or improperly constructed PG (Cox, 1996; Baizman et al.,
2000). It should be noted that functional PG was recently dis-
covered in chlamydia (Pilhofer et al., 2013). This discovery is
very intriguing because existence of PG in chlamydia has been
FIGURE 1 | The DAP/lys anabolic pathways. (A) The synthesis of THDP from aspartate, (B) the acyl pathways, (C) the Ddh pathway, and (D) the DapL
pathway. The abbreviations of the enzymes in addition to the enzymes reaction definitions are listed in Table 1.
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Table 1 | List of DAP/Lys anabolic genes and reaction definitions.
Symbol Gene name Reaction definition
LysC Aspartate kinase ATP + L-aspartate <=> ADP + 4-phospho-L-aspartate
asd Aspartate semialdehyde dehydrogenase L-aspartate 4-semialdehyde + orthophosphate +NADP+ <=>
4-phospho-L-aspartate + NADPH + H+
DapA Dihydrodipicolinate synthase L-aspartate 4-semialdehyde + Pyruvate <=> L-2,3-dihydrodipicolinate +
2H2O
DapB Dihydrodipicolinate reductase 2,3,4,5-tetrahydrodipicolinate + NADP+ <=> L-2,3-dihydrodipicolinate +
NADPH + H+
DapD 2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-acyl-transferase Acyl-CoA + 2,3,4,5-tetrahydrodipicolinate + H2O <=> CoA +
N-acyl-2-L-amino-6-oxoheptanedioate
DapC Acyl-diaminopimelate aminotransferase N-acyl-L,L-2,6-diaminoheptanedioate + 2-oxoglutarate <=>
N-acyl-2-L-amino-6-oxoheptanedioate + L-glutamate
DapE Acyl-diaminopimelate deacylase N-acyl-L,L-2,6-diaminoheptanedioate + H2O <=> acyl +
L,L-2,6-diaminoheptanedioate
Ddh Diaminopimelate dehydrogenase meso-2,6-diaminoheptanedioate + NADP+ + H2O <=>
L-2-amino-6-oxoheptanedioate + NH3 + NADPH
DapL L,L-diaminopimelate aminotransferase L,L-2,6-diaminopimelate + 2-oxoglutarate <=>
2,3,4,5-tetrahydrodipicolinate + L-glutamate +H2O
DapF Diaminopimelate epimerase L,L-2,6-diaminopimelate <=> meso-2,6-diaminopimelate
LysA meso-diaminopimelate decarboxylase meso-2,6-diaminopimelate => L-lysine + CO2
MurE UDP-N-acetylmuramoylalanyl-D-glutamate–2,
6-diaminopimelate ligase
UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimelate:D-
alanyl-D-alanine ligase+ ADP
LysU Lysine -tRNA synthetase ATP + lysine + tRNA(lys) <=> AMP + Diphosphate + L-lysyl-tR
The list was generated using the genomic information deposited in the Integrated Microbial Genomes (IMG) database (http:// img.jgi.doe.gov/ cgi-bin/ w/ main.cgi).
controversial and was known as the chlamydial anomaly due to
the fact that Chlamydia was sensitive to antibiotics that were
known to inhibit PG synthesis, such as D-cycloserine, bacitracin,
and penicillin, yet scientists were not able to detect PG from bac-
teria belonging to the genus. Secondly, protein synthesis would be
suboptimal in a low lys environment, since lys is one of the 20
common amino acid ubiquitously involved in protein synthesis
facilitated by lysine-tRNA synthetase (LysU EC 6.1.1.6). It should
be noted that compounds that are specific for enzymes involved
in the synthesis of DAP/lys pathway would be advantageous, since
these enzymes are absent in humans and therefore likely to be
non-toxic.
The DapL pathway is of interests given the fact the pathway is
narrowly distributed in the bacterial domain based genomic data
mining. As such, this pathway provides an opportunity to explore
the possibility of inhibiting DapL in organisms that employ this
pathway. The DapL pathway is present in Leptospira interrogans
which colonizes the kidney of mammals and is the culprit of the
bacterial disease leptospirosis (Hudson et al., 2008; Evangelista
and Coburn, 2010). The DapL pathway has also been identified
in the intracellular bacterium Chlamydia trachomatis which is
responsible for the sexually transmitted disease (STD) “chlamy-
dia” and is considered themost common STDwith approximately
90 million new cases of infections yearly (Brunham and Rey-
Ladino, 2005; McCoy et al., 2006). In addition, C. trachomatis
is a major cause of blindness in developing countries (Ghuysen
and Goffin, 1999). Chlamydia pneumonia is the causative agent
in approximately 10% of pneumonia cases in infants (Ghuysen
and Goffin, 1999). In this study, the DapL pathway was identified
in some species belonging to the genus Treponema, which is the
causative agent of the STD syphilis (Burstain et al., 1991).
Given the narrow distribution of the DapL pathway in approx-
imately 13% of the genomes of bacteria that have been sequenced
and annotated thus far, and the fact that the majority of bacteria
employ the E. coli-like acyl pathways, DapL is a putative target
for narrow spectrum antibacterial compounds. Access to novel
narrow spectrum antibacterial compounds that are specific for a
certain bacterial species have the potential to avoid risks related to
altering the normal microbiome by killing of normal indigenous
flora that are involved in the production of vitamins, reabsorption
of water and those that are vital for normal physiology among
other roles. This is in contrast to broad-spectrum compounds
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FIGURE 2 | The involvement of m-DAP and lys in the structure of
peptidoglycan (PG) structure. (A) The monomeric unit of PG
showing the disaccharide of GlcNAc and MurNAc. The amino acid at
the highlighted third position is m-DAP in most Gram negative
bacteria and lysine in most Gram positive bacteria. (B) Schematic
showing PG crossing linking with m-DAP to D-alanine in most Gram
negative bacteria and lysine to D-alanine in most Gram positive
bacteria.
that kill both the pathogen and the beneficial bacteria that are a
part of the normal flora (van Saene et al., 1998).
Here we provide a review of the literature pertaining to the dis-
covery of the DapL pathway, structural analyses, inhibitor studies,
evolutionary aspects, and the enzyme as a feasible and plausi-
ble target for the development of narrow-spectrum antibacterial
compounds.
THE DISCOVERY OF THE L,L-DIAMINOPIMELATE
AMINOTRANSFERASE (DapL) VARIANT PATHWAY
The sequence and annotation of the model plant Arabidopsis
thaliana genome provided the opportunity to do comparative
genomics in plants since it was first plant genome to be sequenced
and annotated (The Arabidopsis Genome Initiative, 2000). A
novel variant of DAP/lys pathway was initially suspected in plants
due to the fact that orthologs of dapD, dapC, dapE, and ddh
could not be identified in the genome of the plant using bacterial
or archael protein sequences as queries against the Arabidopsis
genome using tblastn, which is an algorithm that searches trans-
lated nucleotides using protein sequences. However, suitable
orthologs for the other genes known to be involved in the DAP/lys
(dapA, dapB, dapF, and lysA) pathway were readily identified
(Hudson et al., 2005). In addition, enzymatic activity of DapD
and DapC could not be detected from crude protein extracts
prepared from Glycine max, Zea mays, Nictotiana tobacum, and
Chlamydomonas reinhardtii, yet the extract from Z. mays was able
to synthesize lys when the precursor dihydrodipicolinate (DHP)
was provided as a substrate (Hudson et al., 2005). The analyses
from this study suggested that plants bridge the metabolic gap
between THDP and L,L-DAP using a putative aminotransferase
enzyme. The aminotransferase responsible for this activity was
subsequently identified and characterized from A. thaliana (locus
tag At4g33680) and the cyanobacterium Syncechocystis sp. PCC
6803 (locus tag sll0480) using in vitro and in vivo analyses
(Hudson et al., 2006). The fact the gene was identified in a
cyanobacterial species meant that this pathway was a feature of
photosynthetic cohorts in addition to lineages belonging to the
bacterial domain.
KINETIC ANALYSIS OF DapL ENZYMES
Aminotransferases transfer an amino group plus a proton and
an electron pair from a donor molecule, usually an amino acid,
to the carbonyl position of an acceptor molecule, usually a keto
acid (Braunstein, 1973). Kinetic studies of aminotransferases
demonstrated that kinetic mechanism is a two-step process fol-
lowing the bimolecular ping-pong model (Velick and Vavra,
1962). Chemically, in the first step the amino donor forms a Schiff
based structure to pyridoxal-5′-phosphate (PLP). PLP is cova-
lently linked to a conserved lysine residue in the active site of
the enzyme and is a general feature of most aminotransferases
(Alexanxer et al., 1994). In the second step, the 2-keto acid accep-
tor is converted to its amino acid cognate when the amino group
from the donor is transferred to the exposed keto group on the
acceptor (Leipman and Olsen, 2004).
The kinetic properties of several DapL orthologs have been
elucidated to date employing a coupled assay system (Hudson
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et al., 2006). In the forward assay, glutamate serves as the amino
donor and THDP serves as the amino acceptor. In the reverse
assay, L,L-DAP serves as the amino donor and 2-oxoglutarate
(2OG) serves as the amino acceptor (Hudson et al., 2006). The
kinetic properties of eight DapL orthologs with respect to the
Vmax of the forward and reverse directions and the Km for the
four substrates are present in Table 2.
One feature that is apparent from the kinetic analyses is that
the enzyme activity with respect to the Vmax is more robust in the
catabolic (reverse) direction when compared to the anabolic (for-
ward) direction. The enzyme is approximately 58 and 24 times
more efficient for the C. trachomatis and L. interrogans orthologs
respectively (Table 2). This observation is a general feature of all
DapL orthologs that have been fully characterized to date. Initial
in vivo analysis of the plant ortholog showed that the enzyme is
capable of bridging the metabolic gap between THDP and L,L-
DAP using functional complementation of the dap auxotrophic
mutants, namely dapD, dapE, and dapD/E despite being approx-
imately 59 times more efficient in the reverse direction. These
assays showed that DapL, when expressed in E. coli cells harboring
deletion mutations in the dapD and dapE genes, complemented
these mutations when cultured on DAP free media, since the
pathway was to facilitate PG and protein synthesis (Hudson et al.,
2006).
STRUCTURAL ANALYSIS OF DapL ORTHOLOGS
DapLs are approximately 400 amino acids in length and belong
to the pyridoxal-5′-phosphate (PLP) dependent family of class
I/II aminotransferases. It was demonstrated through phyloge-
netic analysis that there are two divergent forms of the enzyme
namely the Type I and Type II. The two types share approxi-
mately 30% homology on the amino acid level (Hudson et al.,
2008). The structures of three DapLs have been solved to date
using x-ray crystallography. The A. thaliana ortholog was the
first DapL ortholog to be structurally characterized (Watanabe
et al., 2007) followed by the structure of the ortholog from the
alga C. reinhardtii and subsequently from C. trachomatis (Dobson
et al., 2011; Watanabe et al., 2011). The overall 3-dimenisional
structures of the DapL orthologs that have been solved are
depicted in Figures 3A–C. The crystal structures revealed that
the holoenzyme is active as a dimer, which is consistent with
the majority of aminotransferases (Watanabe et al., 2007). The
plant enzyme also revealed that eachmonomeric unit consisted of
two domains namely large domain (LD) and small domain (SD)
both of which belong to a α/β class (Watanabe et al., 2007). The
α/β structure of each monomer represents a V-shaped conforma-
tion that comprises the PLP fold involved in the transamination
process. A malate-bound structure of the Arabidopsis ortholog
facilitated the modeling of two substrates L,L-DAP and glutamate
into the active site of the enzyme was instrumental in elucidat-
ing amino acid that are involved in the active site of the enzyme
(Watanabe et al., 2007). Interestingly, unlike the Arabidopsis and
Chlamydomonas ortholog, the Chlamydia ortholog was found
to be promiscuous regarding substrate specificity due to the fact
that the enzyme was able to use both racemic DAP isomers
as substrates (McCoy et al., 2006). The crystal structure of the
DapL ortholog from C. trachomatis revealed that this promiscu-
ity could be the result of active-site flexibility due to the open
conformation having a 9.5 Å degree of opening of the SD of
the monomer making a wider V-shaped active site (Figure 3B).
This open SD conformation allows the hinge region more flexi-
bility, which could lead to substrate specificity when compared to
the A. thaliana and C. reinhardtii orthologs (Dobson et al., 2011;
Watanabe et al., 2011).
INHIBITOR STUDIES OF DapL
Given the fact that DapL is a plausible target for the devel-
opment of antibacterial compounds, herbicides or algaecides,
it was logical that inhibitor strategies would be explored. To
that end, 29,201 drug-like compounds were screened against the
Arabidopsis ortholog (Fan et al., 2010). The IC50 values of 46 of
the compounds were determined based on the fact that they were
able to inhibit enzyme activity of at least 13% (Fan et al., 2010).
In addition, aryl hydrazide and rhodanine modifications were
used for the generation of 20 additional analogs in an attempt
to elucidate structure-activity relationship (SAR), which are use-
ful in guiding the development of drugs that could be potential
biocides (Fan et al., 2010). One of the compounds identified in
the initial screen was an o-sulfonamido-arylhydrazide, which is a
reversible inhibitor with an IC50 ∼ 5μM. Further modifications
Table 2 | Kinetic properties of DapL orthologs.
Enzyme Vmax (Forward) Vmax(Reverse) Km(L,L-DAP) μM Km (THDP) μM Km (2-OG) mM Km (Glu) mM Citations
AtDapL 0.38 22.3 67.0 38.0 8.7 1.9 Hudson et al., 2006
CtDapL 0.01 0.58 116 19.0 2.1 4.0 McCoy et al., 2006
PcDapL 0.09 1.84 6.0 5.0 1.1 0.4 McCoy et al., 2006
CrDapL 0.68 11.6 300.0 100.0 2.2 0.9 Dobson et al., 2011
LiDapL 0.45 10.6 37.0 14.0 0.4 4.3 Hudson et al., 2008
MtDapL 0.10 6.30 82.0 7.8 2.6 1.1 Hudson et al., 2008
DhDapL 0.007 0.4 38.2 9.1 0.7 10.1 Hudson et al., 2008
MtDapL* 0.006 0.25 60.4 14.0 0.3 4.2 Hudson et al., 2008
The Vmax for the forward and reverse are in µmol min−1 mg−1 of purified recombinant protein. The enzyme abbreviations are as follows AtDapL (Arabidopsis
thaliana), CtDapL (Chlamydia trachomatis), PcDapL (Protochlamydia amoebophila), CrDapL (Chlamydomonas reinhardtii), LiDapL (Leptospira interrogans), MtDapL
(Methanothermobacter thermautotrophicus), DhDapL (Desulfitobacterium hafniense), and MtDapL* (Moorella thermoacetica).
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FIGURE 3 | Three -dimensional representation of DapL orthologs
showing the dimeric structure of the enzyme from (A) the plant
Arabidopsis thaliana (PDB id: 3E17), (B) the bacterium Chlamydia
trachomatis (PDB id: 3ASA), and (C) the alga Chlamydomonas
reinhardtii (PDB id: 3QGU). The arrows show the two active sites in the
dimer (Adapted from McKinnie et al., 2014).
of o-sulfonamido-arylhydrazide led to the identifications of
compounds that are have increased inhibitory characteristics (Fan
and Vederas, 2012). Structural modeling and protein alignment
of DapLs from V. spinosum, L. interrogans using the structural
data from the A. thaliana, C. trachomatis, and C. reinhardtii
orthologs showed that the amino acids that comprise the active
site of DapL are conserved. In addition, this analysis revealed
that the overall active site shape was very similar for the five
orthologs. Despite this similarity on the structural level, it was
shown that there is differential response of DapL to antibiotic
lead compounds based on the IC50 values ranging from 4.7 to
250μM the orthologs using inhibitors with structural moiety of a
hydrazide, rhodanine, barbiturate and thiobarbiturate (McKinnie
et al., 2014). This could perhaps be explained by the protein
dynamics; the orthologs share an average structure, as determined
by x-ray crystallography, but deviate in the proportion of sub-
structures. It should be noted that it is still unclear whether the
inhibitors of DapL that have been discovered thus far are specific
for DapL or inhibit aminotransferases in general. In addition, the
inhibitor/enzyme interactions pertaining to the actual binding
site(s) of the inhibitor to the enzyme are still not clear.
THE DISTRIBUTION OF DapL IN THE DOMAIN BACTERIA
To assess the DapL frequency in the bacterial domain, bacterial
proteins were extracted and downloaded from themicrobial com-
plete genome from the NCBI database as of 5/23/2014. Using
the Interproscan5 (Jones et al., 2014), the proteins were then
scanned for domains and the resulting list was queried for hits
containing IPR019942 which is a signature protein domain for
DapL proteins. This search resulted in the identification of 381
out of 2771 bacteria that possessed at least one putative DapL
(Supplementary Table 1). The analysis expanded the list of bacte-
rial lineages that were known to contain the DapL pathway from
only a few years ago when the pathway was only found in lineages
of Cyanobacteria, Desulfuromonadales, Firmicutes, Bacteriodes,
Chalmydiae, Spirochaeta, and Chloroflexi (Hudson et al., 2008;
Fan and Vederas, 2012). The phylogenetic relationship of DapL
orthologs associated with pathogens and those with evidence at
the protein levels are depicted in Figure 4. Interestingly, the phy-
logenic tree includes four species from the genus Treponema,
which are known to be involved in human pathogenesis (Burstain
et al., 1991). DapL has not been experimentally confirmed in
any species belonging to Treponema. Given that it is an impor-
tant bacterial lineage regarding pathogenicity, a genome context
scan was performed to assess if the dapL gene identified in the
species were in an operon like structure with genes that are
known to be involved in DAP/lys anabolism. The result from this
analysis show that the putative dapL orthologs from Treponema
azotonutricum and Treponema primitia are proximal to gene(s)
that are known to be involved in DAP/lys synthesis. The genomic
context in Treponema azotonutricum is very convincing and sug-
gests that the identified ortholog is probably an authentic dapL
given the fact that the ortholog is proximal to five other genes
that are involved in DAP/lys synthesis missing only the dapF in
the structure to complete the synthesis of DAP/lys. It should be
noted that the dapF gene is present in another location in the
genome of T. azotonutricum to complete the synthesis of DAP/lys
de novo (Figure 5). The DapL orthologs from T. azotonutricum
and T. primitia share 54 and 52% identical to the A. thaliana
ortholog respectively.
DapL AS A TARGET FOR NARROW-SPECTRUM
ANTIBACTERIAL DEVELOPMENT
There are several factors that make DapL a feasible and plausible
target for antibiotic development. Firstly, the enzyme is involved
in a pathway that synthesizes an essential amino acid and PG,
which are both absent in the humans. In addition, the path-
way is narrowly distributed, which makes it a putative target for
a narrow-spectrum antibiotic. This is because the majority of
bacteria utilize the acyl pathways for DAP/lys synthesis and inhi-
bition of the other enzymes in the pathway have the potential
to be very detrimental regarding the killing of beneficial bacte-
ria. In addition, in the majority of bacteria that contain dapL, the
DapL pathway is the sole route toward DAP/lys synthesis (Hudson
et al., 2008; Nachar et al., 2012). The only exceptions that have
been experimentally confirmed are in the genomes of Bacterioides
fragilis and Clostridium thermocellum, which were found to con-
tain both the Ddh and DapL pathways (Hudson et al., 2011).
A search of the bacterial proteomes using the protein signature
IPR010190, which is a signature of Ddh, revealed that C. tra-
chomatis, L. interrogans, and Treponema sp. do not contain a Ddh
enzyme in addition to the acyl pathway enzymes. It should be
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FIGURE 4 | The evolutionary history of selected DapL as inferred by
using the Maximum Likelihood method based on the LG model.
Branches corresponding to partitions that were reproduced in less than 50%
of aLRT SH-like supports are collapsed. Clades containing more than 4 taxa
with similar species name are compressed and indicated with a black circle
next to the node. The tree is drawn to scale, with branch lengths measured in
the number of substitutions per site. DapC sequences were chosen as out
group and used to root the tree. DapL with the prefix “EP” have been
experimentally validated in previous studies (Hudson et al., 2006, 2008, 2011;
McCoy et al., 2006; Nachar et al., 2012).
FIGURE 5 | Genomic context of DAP/lys genes from the bacteria
Treponema azotonutricium ZAS-9 and Treponema primitia ZAS 2. The
information was obtained by searching the Integrated Microbial Genome
database (https://img.jgi.doe.gov/cgi-bin/w/main.cgi) using the locus tags
TREAZ_1309 and TREPR_1185. The color of each arrow represents a
particular gene as denoted in the figure.
noted that some aminotransferases are promiscuous regarding
substrate specificity. For example, the E. coli aspartate amino-
transferase, tyrosine aminotransferase, and the branched-chain
aminotransferase have been shown to have overlapping activities
(Gu et al., 1998). In addition, a recent study demonstrated that
three aminotransferases are involved in alanine biosynthesis in
E. coli (Yoneyama et al., 2011). Therefore, whether other amino-
transferases exist in eubacteria that are capable of catalyzing the
direct conversion of THDP to L,L-DAP to facilitate PG and lys
biosynthesis is still not known and awaits experimentation. If the
dapL gene is essential in eubacteria as it is in plants then the
enzyme would be plausible target for antibacterial development.
A point that should be taken into consideration is the possi-
bility of bacteria acquiring lys from the host using amino acid
transport systems, which are ubiquitously found in prokary-
otes (Burkovski and Krämer, 2002). A lys specific transporter
encoded by the lysP gene exists in E. coli. This permease belongs to
the amino acid, polyamine, and organocation (APC) transporter
family (Steffes et al., 1992). Although it is possible to synthesize
lys from DAP, it is not possible to synthesize DAP from lys to
facilitate PG biosynthesis in bacteria that require m-DAP as the
cross-linking amino acid. This would require an enzyme (lysine
carboxylase) capable of adding a carboxyl group to lys to make
m-DAP, which to our knowledge has never been described. In
addition, the inhibition of lys biosynthesis would preclude the
bacteria from synthesizing permeases since lys is one of the amino
acids that is needed to construct these proteins. For example,
the LysP protein from E. coli K-12 substs MG1655 (NP_416661)
is 489 amino acids and contains 14 lys residues. Another point
that should be considered is that even if the bacterium is able
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FIGURE 6 | The figure is a schematic representation of the protein
translational system in bacteria. (A) The normal process where the tRNA
charged with the appropriate amino acid (the fuel) is able to facilitate
protein synthesis (the engine). (B) Bactericidal or bacteriostatic effect due
to lack of the appropriate amino acid to facilitate protein synthesis. The 50S
and 30S ribosomal subunits are shown with the E (exit site), P (peptidyl
site), and the A (aminoacyl site).
to sequester lys through passive transport means, the rate of
incorporation would unlikely to be equal to the rate of protein
synthesis. This scenario would probably lead to stalling of the
translational system due to the fact that lys would not be readily
available to charge the lys specific tRNA to facilitate protein syn-
thesis. Under this condition it would lead to either a bactericidal
or bacteriostatic effect (Figure 6).
SUMMARY
The protein translation machinery is an established target
for antibacterial compounds given the fact that antibiotic
classes, such as tetracyclines, aminoglycodies, streptogramins,
macrolides, and lincosamides, inhibit the ribosomal machinery
which we define as “the engine” of the translation system by
specifically binding to the 30S ribosomal subunit (Davies and
Davies, 2010) (Table 3). This raises the question of whether it
is plausible and feasible to inhibit the incorporation of amino
acids which we define in this context as “the fuel” for the system
specifically the essential amino acids as a mean of antibacterial
development. An essential amino acid such as lysine would be a
novel antibacterial target since the current targets are relegated
to PG biosynthesis, translation, DNA replication, C1 metabolism,
transcription, and cell membrane (Table 3). The idea of amino
acid biosynthesis inhibition as a biocide is not novel. In fact,
the inhibition mechanism of the herbicide glyphosate commonly
referred to as Roundup™ was elucidated in the early 1970s
by Monsanto scientists and was shown to be a nonselective
herbicide that inhibits the enzyme enolpyruvylshikimate phos-
phate synthase which is involved in the synthesis of the amino
acids, tyrosine (tyr), phenylalanine (phe), and tryptophan (trp)
(Williams et al., 2000). It should be noted that the pathway for
tyr, phe, and trp through to the central metabolite chorismate is
Table 3 | Families, targets, and examples of antibiotics (Adapted from
Davies and Davies, 2010).
Families Target Example(s)
β-lactams
Glycopeptides
Peptidoglycan
biosynthesis
Penicillins
Cephalosporins
Penems
Monobactams
Vancomycin
Teicoplanin
Tetracyclines
Aminoglycosides
Streptogramins
Macrolides
Lincosamides
Translation Minocycline
Tigecycline
Gentamicin
Streptomycin
Spectinomycin
Synercid
Erythromycin
Azithromycin
Clindamycin
Quinolones DNA replication Ciprofloxacin
Pyrimidines
Sulfonamides
C1 metabolism Trimethoprim
Sulfamethoxazole
Rifamycins Transcription Rifampin
Lipopeptides
Cationic peptides
Bacterial cell membrane Daptomycin
Colistin
not present in the animal kingdom which makes the glyphosate
a superior herbicide and being non-toxic to humans. As such,
the lack of genetic machineries to anabolize the essential amino
acids provide an opportunity to explore the feasibility and plau-
sibility of identifying and or developing compounds that can
be used as chemotherapies as antibacterial agents. These com-
pounds would be advantageous in combating the rise in antibi-
otic resistant bacteria in addition to emerging infections and
diseases.
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